Ozempic, a type 2 diabetes drug that has increasingly been used to help with weight loss, will now be labeled as having the potential to block intestines.
The U.S. Food and Drug Administration recently made the label update for the drug made by Novo Nordisk, without directly citing Ozempic as the cause for this condition.
“Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure,” the label reads.
